The company’s IPO offered 8.8 million shares of common stock at a price of $15 per share to the public.
Piper Jaffray & Co., Barclays Capital and Wells Fargo Securities acted as joint book-running managers for the offering.
K2M is a global medical device company focused on designing, developing and commercializing complex spine technologies, techniques and minimally invasive procedures.
More Articles on Devices:
5 Key Results: LDR’s Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE’s Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018
